Interleukin-6 in Patients With Heart Failure and Preserved Ejection Fraction
Alessio Alogna(Deutsches Herzzentrum der Charité), Barry A. Borlaug(Mayo Clinic), James L. Kirkland(Cedars-Sinai Medical Center), Mark C. Petrie(British Heart Foundation), Hidemi Sorimachi(Gunma University), Margaret M. Redfield(Mayo Clinic in Arizona), Tamar Tchkonia(Cedars-Sinai Medical Center), Katlyn E. Koepp(Mayo Clinic), Carolyn S.P. Lam(University of Glasgow), Michael S. Sabbah(Mayo Clinic), Adriaan A. Voors(University Medical Center Groningen), Paul M. Ridker(Herlev Hospital), Masaru Obokata(Gunma University), Jair Machado Espindola Netto(Mayo Clinic), Michael D. Jensen(Mayo Clinic)
Cited by 111
Related Papers
2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
|European Heart Journal|2021|13.1k
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
|New England Journal of Medicine|2017|9.1k
ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC
|European Heart Journal|2012|6.9k
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
|New England Journal of Medicine|2019|6.8k
Empagliflozin in Heart Failure with a Preserved Ejection Fraction
|New England Journal of Medicine|2021|4.6k